We are pleased to announce that Opera Therapeutics is the latest company to join the Kairos portfolio.
Founded in 2017 Opera Therapeutics is a biopharmaceutical company that is developing next-generation treatments for ocular and neurological diseases.
“Opera is delighted to have secured this investment from Kairos Ventures to support the development of a truly novel biologic with the ability to regulate vascular integrity, control inflammation, and promote neuronal survival. This investment will help Opera improve the lives of patients with retinopathies as well as those suffering from neurovascular diseases for which treatment options are sorely limited.”
– Peter Alff, President of Opera Therapeutics
Diabetic Retinopathy is the leading cause of vision loss in adults worldwide. Opera Therapeutics is developing treatments based on technology from Columbia University that harnesses a natural cellular mechanism to prevent the damage and cell death that are hallmarks of Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO) which account for the majority of vision loss amongst people with diabetes. Opera Therapeutics is additionally exploring the utility of their biologics for treating stroke-induced edema in the brain.
The funding provided by Kairos Ventures will help Opera improve the lives of patients with retinopathies as well as those suffering from neurovascular diseases for which treatment options are sorely limited. As part of the investment, Peter Alff will join the Opera Therapeutics Board. “Opera is delighted to have secured this investment from Kairos Ventures to support the development of a truly novel biologic with the ability to regulate vascular integrity, control inflammation, and promote neuronal survival,” said Peter Alff, President of Opera Therapeutics. “This investment will help Opera improve the lives of patients with retinopathies as well as those suffering from neurovascular diseases for which treatment options are sorely limited.”
We are excited about our investment in Opera Therapeutics and welcome them to the extended Kairos Ventures family!
